Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection

P. L. A. Fraaij; E. van der Vries; M. F. C. Beersma; A. Riezebos-Brilman; H. G. M. Niesters; A. A. van der Eijk; M. D. de Jong; D. Reis Miranda; A. M. Horrevorts; B. U. Ridwan; M. J. H. M. Wolfhagen; R. J. Houmes; J. T. van Dissel; R. A. M. Fouchier; A. C. M. Kroes; M. P. Koopmans; A. D. M. E. Osterhaus; C. A. B. Boucher

doi:https://doi.org/10.1093/infdis/jir397

Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection

P. L. A. Fraaij, E. van der Vries, M. F. C. Beersma, A. Riezebos-Brilman, H. G. M. Niesters, A. A. van der Eijk, M. D. de Jong, D. Reis Miranda, A. M. Horrevorts, B. U. Ridwan, M. J. H. M. Wolfhagen, R. J. Houmes, J. T. van Dissel, R. A. M. Fouchier, A. C. M. Kroes, M. P. Koopmans, A. D. M. E. Osterhaus, C. A. B. Boucher

Medical Microbiology and Infection Prevention (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

39 Citations (Scopus)

Abstract

A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated

Original language	English
Pages (from-to)	777-782
Journal	Journal of infectious diseases
Volume	204
Issue number	5
DOIs	https://doi.org/10.1093/infdis/jir397
Publication status	Published - 2011

Access to Document

https://doi.org/10.1093/infdis/jir397

Cite this

Fraaij, P. L. A., van der Vries, E., Beersma, M. F. C., Riezebos-Brilman, A., Niesters, H. G. M., van der Eijk, A. A., de Jong, M. D., Reis Miranda, D., Horrevorts, A. M., Ridwan, B. U., Wolfhagen, M. J. H. M., Houmes, R. J., van Dissel, J. T., Fouchier, R. A. M., Kroes, A. C. M., Koopmans, M. P., Osterhaus, A. D. M. E., & Boucher, C. A. B. (2011). Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. Journal of infectious diseases, 204(5), 777-782. https://doi.org/10.1093/infdis/jir397

@article{f3497a6ff4194416bec550051949cedc,

title = "Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection",

abstract = "A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated",

author = "Fraaij, {P. L. A.} and {van der Vries}, E. and Beersma, {M. F. C.} and A. Riezebos-Brilman and Niesters, {H. G. M.} and {van der Eijk}, {A. A.} and {de Jong}, {M. D.} and {Reis Miranda}, D. and Horrevorts, {A. M.} and Ridwan, {B. U.} and Wolfhagen, {M. J. H. M.} and Houmes, {R. J.} and {van Dissel}, {J. T.} and Fouchier, {R. A. M.} and Kroes, {A. C. M.} and Koopmans, {M. P.} and Osterhaus, {A. D. M. E.} and Boucher, {C. A. B.}",

year = "2011",

doi = "https://doi.org/10.1093/infdis/jir397",

language = "English",

volume = "204",

pages = "777--782",

journal = "Journal of infectious diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

Fraaij, PLA, van der Vries, E, Beersma, MFC, Riezebos-Brilman, A, Niesters, HGM, van der Eijk, AA, de Jong, MD, Reis Miranda, D, Horrevorts, AM, Ridwan, BU, Wolfhagen, MJHM, Houmes, RJ, van Dissel, JT, Fouchier, RAM, Kroes, ACM, Koopmans, MP, Osterhaus, ADME & Boucher, CAB 2011, 'Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection', Journal of infectious diseases, vol. 204, no. 5, pp. 777-782. https://doi.org/10.1093/infdis/jir397

Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. / Fraaij, P. L. A.; van der Vries, E.; Beersma, M. F. C. et al.
In: Journal of infectious diseases, Vol. 204, No. 5, 2011, p. 777-782.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection

AU - Fraaij, P. L. A.

AU - van der Vries, E.

AU - Beersma, M. F. C.

AU - Riezebos-Brilman, A.

AU - Niesters, H. G. M.

AU - van der Eijk, A. A.

AU - de Jong, M. D.

AU - Reis Miranda, D.

AU - Horrevorts, A. M.

AU - Ridwan, B. U.

AU - Wolfhagen, M. J. H. M.

AU - Houmes, R. J.

AU - van Dissel, J. T.

AU - Fouchier, R. A. M.

AU - Kroes, A. C. M.

AU - Koopmans, M. P.

AU - Osterhaus, A. D. M. E.

AU - Boucher, C. A. B.

PY - 2011

Y1 - 2011

N2 - A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated

AB - A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated

U2 - https://doi.org/10.1093/infdis/jir397

DO - https://doi.org/10.1093/infdis/jir397

M3 - Article

C2 - 21844304

SN - 0022-1899

VL - 204

SP - 777

EP - 782

JO - Journal of infectious diseases

JF - Journal of infectious diseases

IS - 5

ER -